Surmodics, Inc.
SRDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -7.18 | -0.54 | -4.63 | 0.73 |
| FCF Yield | 0.21% | 0.14% | -1.45% | 0.57% |
| EV / EBITDA | -82.14 | -109.61 | 26,972.84 | 546.28 |
| Quality | ||||
| ROIC | -3.11% | -2.95% | -2.02% | -1.16% |
| Gross Margin | 70.99% | 72.12% | 75.19% | 73.89% |
| Cash Conversion Ratio | -0.26 | -0.18 | 2.16 | -1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.57% | 5.69% | 7.18% | 8.05% |
| Free Cash Flow Growth | 43.49% | 107.69% | -363.03% | 204.14% |
| Safety | ||||
| Net Debt / EBITDA | -1.20 | -0.90 | 137.24 | -2.87 |
| Interest Coverage | -6.06 | -4.69 | -2.81 | -0.69 |
| Efficiency | ||||
| Inventory Turnover | 0.54 | 0.49 | 0.49 | 0.57 |
| Cash Conversion Cycle | 179.30 | 214.22 | 221.73 | 191.22 |